FindTrial
Sign In

fludarabine and cyclophosphamide

DRUG6 trials

Sponsors

Beijing Immunochina Medical Science & Technology Co., Ltd., Peking University, Chinese PLA General Hospital, Affiliated Hospital to Academy of Military Medical Sciences, University of Maryland, Baltimore

Conditions

B-Cell LymphomaChronic Lymphocytic LeukemiaDiffuse Large B Cell Lymphoma (DLBCL)Follicular LymphomaHigh-risk Plasma Cell NeoplasmsLeukemiaLymphomas/Leukemias With Plasmacytic DifferentiationMantle Cell Lymphoma

Early Phase 1

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Not yet recruitingNCT06986434
Affiliated Hospital to Academy of Military Medical SciencesLymphomas/Leukemias With Plasmacytic Differentiation, Relapsed or Refractory Plasma Cell Neoplasms
Start: 2026-04-02End: 2028-08-25Target: 20Updated: 2026-04-08
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms
RecruitingNCT07416682
Affiliated Hospital to Academy of Military Medical SciencesHigh-risk Plasma Cell Neoplasms
Start: 2026-04-14End: 2028-01-30Target: 20Updated: 2026-07-13

Phase 1

Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)
CompletedNCT03173417
Beijing Immunochina Medical Science & Technology Co., Ltd.Leukemia
Start: 2017-05-23End: 2019-05-01Updated: 2019-05-20
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
NCT03208556
Peking UniversityRelapsed or Refractory B-cell Lymphoma
Start: 2017-06-21End: 2020-06-01Target: 20Updated: 2017-09-14
Chidamide Bridging for CAR-T Therapy
RecruitingNCT05370547
Chinese PLA General HospitalNon Hodgkin's Lymphoma
Start: 2022-05-25End: 2025-06-30Target: 120Updated: 2024-03-06
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Enrolling by invitationNCT07168486
University of Maryland, BaltimoreB-Cell Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) +7
Start: 2024-10-28End: 2028-07-01Target: 15Updated: 2026-09-14

Related Papers

CD72 as a complementary B-lineage marker for longitudinal measurable residual disease surveillance after CD19 CAR-T therapy in R/R B-ALL.
2026-08-03
Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant
Blood2022-11-151 citations
Factors Associated with Outcomes Among Refractory/Relapsed TP53-Mutated/Chromosome 17p Deletion Acute B-Cell Lymphoblastic Leukemia (B-ALL) Patients Treated with CD19-Targeted Chimeric Antigen Receptor (CAR)-T Therapy
Blood2021-11-053 citations
Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy
Leukemia & lymphoma/Leukemia and lymphoma2021-10-2116 citations
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.
2021-08-0736 citations
Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Blood2020-11-044 citations
Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients
Blood2020-11-043 citations
Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant
Blood2020-11-042 citations
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
Blood Advances2020-05-26206 citations
Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Blood2019-11-134 citations
Efficacy and Safety of CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphocytic Leukemia (B-cell ALL) in a Large Cohort Including Patients with Extramedullary Disease(EMD), High Leukemia Burden, BCR-ABL (+) Mutation,TP53 Mutation, and Post-Transplant Relapse
Blood2018-11-297 citations
Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.
Journal of Clinical Oncology2018-05-2015 citations